Get the Stockscreener App
1.39
1.46%
0.02
After Hours:
1.41
0.02
+1.44%
Inovio Pharmaceuticals Inc stock is traded at $1.39, with a volume of 1.87M.
It is up +1.46% in the last 24 hours and down -28.72% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$1.37
Open:
$1.36
24h Volume:
1.87M
Relative Volume:
1.36
Market Cap:
$50.98M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.2282
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
+2.21%
1M Performance:
-28.72%
6M Performance:
-33.17%
1Y Performance:
-86.61%
1-Day Range:
$1.36
$1.44
1-Week Range:
$1.30
$1.44
52-Week Range:
$1.30
$12.33
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.39 | 69.31M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
What drives Inovio Pharmaceuticals Inc. stock priceBreakthrough capital growth - Autocar Professional
What analysts say about Inovio Pharmaceuticals Inc. stockOutstanding trading profits - jammulinksnews.com
Is Inovio Pharmaceuticals Inc. a good long term investmentRecord-breaking capital gains - jammulinksnews.com
Inovio Pharmaceuticals Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
What makes Inovio Pharmaceuticals Inc. stock price move sharplyFree Smart Money Stock Analysis - beatles.ru
INOVIO to Present DNA Medicine Innovations for Rare Diseases at Orphan Drug Summit - MyChesCo
Inovio wins new Overweight at Piper Sandler on potential FDA nod for lead drug - MSN
INOVIO Announces Pricing of $25 Million Public Offering - Kilgore News Herald
Inovio Pharmaceuticals (INO) Set for Growth With Potential FDA N - GuruFocus
Inovio stock on Piper Sandler's bullish view (INO:NASDAQ) - Seeking Alpha
This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Piper Sandler Initiates Inovio Pharmaceuticals at Overweight With $5 Price Target - MarketScreener
Inovio (INO) Gains Favorable Analyst Rating with $5 Price Target - GuruFocus
Inovio Pharmaceuticals Announces Public Offering Agreement - The Globe and Mail
INOVIO Pharmaceuticals: Pioneering Rare Disease Therapies with DNA-Encoded Antibodies - AInvest
INOVIO to Present at Upcoming Scientific Conference - StreetInsider
INOVIO to Present at Upcoming Scientific Conference | INO Stock News - GuruFocus
INOVIO Announces Public Offering of Common Stock and Warrants - MSN
Inovio Pharmaceuticals announces proposed public offering of common stock and warrants - MSN
Inovio Pharmaceuticals Plunges 29.44% on $25M Offering - AInvest
Inovio Stock’s Unexpected Dive - StocksToTrade
INOVIO Announces Pricing of $25 Million Public Offering | INO Stock News - GuruFocus
Inovio prices $25 million public offering of common stock and warrants - Investing.com
Inovio prices $25 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
INOVIO announces proposed public offering of common stock By Investing.com - Investing.com South Africa
INOVIO Pharma Announces Proposed Public Offering - Nasdaq
Inovio Pharmaceuticals (INO) Announces Public Offering Plan - GuruFocus
Inovio Pharma dives on equity offering plans - TradingView
Inovio Pharmaceuticals stock plunges after announcing public offering - Investing.com
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from Russell Small Cap Completeness Index - MarketScreener
Inovio Pharmaceuticals, Inc.(NasdaqCM: INO) dropped from Russell 3000 Value Index - MarketScreener
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - MSN
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - AllSides
Human DNA Vaccines Market Set to Witness Breakthrough Advances - openPR.com
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Position Boosted by Bank of America Corp DE - Defense World
Deutsche Bank AG Has $164,000 Stock Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Northern Trust Corp Grows Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia
Inovio shareholders approve board nominees and proposals By Investing.com - Investing.com Canada
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):